A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects.
Chris WynneChristian SchwabeSonica Sachdeva BatraLuis Lopez-LazaroSuresh KankanwadiPublished in: British journal of clinical pharmacology (2018)
PK, safety and immunogenicity of DRL_BZ were comparable to EU-approved and US-licensed bevacizumab in healthy male subjects.
Keyphrases